MedTrace Logo

Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer

NCT00622349 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 707

Last updated 2013-01-30

No results posted yet for this study

Summary

The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Cisplatin, Ifosfamide, Gemcitabine

Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks

DRUG

Ifosfamide, Gemcitabine

Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks

DRUG

Cisplatin, docetaxel

Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks

Sponsors & Collaborators

  • European Lung Cancer Working Party

    lead OTHER

Principal Investigators

  • Jean-Paul Sculier, MD, PhD · European Lung Cancer Working Party

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2009-03-31
Completion
2009-12-31

Countries

  • Belgium
  • France
  • Greece
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00622349 on ClinicalTrials.gov